周荣明 黄铁球

    摘 要 目的：探讨左西孟旦辅助治疗急性心力衰竭患者疗效及对N末端脑钠肽前体(NT-proBNP)和预后的影响。方法：将80例急性心力衰竭患者根据随机数字表法将其分为对照组和观察组各40例，对照组使用常规基础治疗，观察组在常规治疗基础上增加左西孟旦辅助治疗。比较两组疗效、治疗前后NT-proBNP指标、不良反应率和30 d内主要不良心血管事件发生率。结果：观察组治疗总有效率高于对照组、NT-proBNP和30 d内主要不良心血管事件低于对照组(均P<0.05)；两组不良反应比较无统计学意义(P>0.05)。结论：左西孟旦辅助治疗急性心力衰竭患者疗效较好，能改善NT-proBNP，且安全性较高、预后较好。

    关键词 左西孟旦 临床疗效 急性心力衰竭

    中图分类号：R972.1； R541.61 文献标志码：B 文章编号：1006-1533(2021)23-0028-03

    Curative effect of levosimendan adjuvant therapy on acute heart failure and its influence on NT-proBNP level and prognosis

    ZHOU Rongming1， HUANG Tieqiu2(1. Department of Emergency， the People’s Hospital of Yushan County， Shangrao 334700， China； 2. Department of Cardiology， the Second Hospital affiliated to Nanchang University， Nanchang 330000， China)

    ABSTRACT Objective： To investigate the effect of levosimendan in the adjuvant treatment of patients with acute heart failure and its influence on N-terminal pro-brain natriuretic peptide (NT-proBNP) level and prognosis. Methods： Eighty patients with acute heart failure were divided into a control group (n=40) and an observation group (n=40) based on a random number table method. The efficacy ......